(icTV) CLINICAL TRIALS RESULTS

Plasma angiopoietin-2 & ARDS risk in sepsis

In this icTV interview, presenter John Reilly discusses his clinical trial “Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: Evidence from mendelian randomisation and mediation analysis”. Full results from this trial were presented at the clinical trials session at LIVES 2018 in Paris and published in Intensive Care Medicine.

Read this article in Intensive Care Medicine here.

Watch the full session including this presentation here.

#LIVES2018 #sepsis